CEL-SCI Reports 2nd Consecutive Month of Record Patient Enrollment in 2015 for Its Phase III Head and Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT: CVM) today announced that in February it has enrolled 25 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). This follows January's prior record. A total of 377 patients have been enrolled in the world's largest Phase III study in head and neck cancer as of February 28, 2015. "We are pleased to have achieved this consecutive month of record enrollment in 2015, particularly in light of the fact that February was a shorter month. During the month of February we also had a record number of patient screenings. During the month of February we also received clearance in the Philippines, Malaysia and Belarus to begin patient enrollment in those countries. This is expected to result in an even higher number of patients being enrolled in the study in March," stated CEL-SCI Chief Executive Officer Geert Kersten. The goal is to enroll a total of 880 patients through approximately 100 clinical centers in about 25 countries by the end of 2015. About Multikine Phase III Study The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in the overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care (SOC) vs. subjects who are treated with SOC only.